MS Blood Tests May Flag When Treatment Stops Working

Credibility

Interest

Share:2 min read

Key Takeaway

If certain immune cells do not rise in a routine blood test after starting natalizumab, it may be a sign that the MS treatment needs a closer check.

What They Found

Natalizumab helps keep immune cells from entering the brain and spinal cord, so more of these cells usually remain in the blood. In a clinical trial, blood counts generally rose within 12 weeks for people taking the drug, but not for people taking a placebo, which had no active drug. The rise was also absent in people who kept making antibodies against natalizumab—proteins that can block the treatment. A clear rise in immune cells helped researchers identify people who did not have these antibodies. The researchers also examined records from an MS clinic to explore how blood counts related to antibodies, drug levels, and MS activity.

Who Should Care and Why

People starting natalizumab may benefit from asking their MS team how their blood counts compare with their count before treatment. A blood count is a routine test, so it may offer an early clue without waiting for new MS symptoms. If the expected rise is missing, a clinician may consider a separate test for antibodies against the drug. Caregivers can help by keeping track of test results and bringing questions to appointments. For care teams, this clue could help them decide when to check whether the treatment is working as expected.

Important Considerations

A missing rise in immune cells is a clue, not proof that someone has antibodies or that treatment has failed. The blood-count pattern needs to be compared with a count taken before treatment, so one result alone may not tell the full story. The study suggests this approach could lead to earlier antibody testing, but it does not show that using it prevents new MS activity.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Diagnostics Clinical Trials

Article Topics:

anti-drug antibodyimmunogenicityimmunotherapymultiple sclerosisnatalizumab

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News